Encapsulated cell therapy - Rogosin Institute/Metromedia Bio-Science

Drug Profile

Encapsulated cell therapy - Rogosin Institute/Metromedia Bio-Science

Alternative Names: Cancer cell-containing agarose-agarose macrobeads; Cancer inhibitor macrobead - Metromedia Bio-Science; Macrobead biological anti-tumour therapy; Macrobead cancer therapy - Rogosin Institute; Macrobeads; Mouse renal adenocarcinoma cell-containing agarose-agarose macrobeads; Mouse renal carcinoma (RENCA) macrobeads; RENCA macrobeads

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rogosin Institute
  • Class Antineoplastics; Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 16 Aug 2015 Encapsulated cell therapy is still in phase II trials for Pancreatic cancer (Refractory metastatic disease) in the USA
  • 16 Aug 2015 Encapsulated cell therapy is still in phase II trials for Prostate cancer (Refractory metastatic disease) in the USA
  • 16 Aug 2015 Encapsulated cell therapy is still in phase II trials for Colorectal cancer (Refractory metastatic disease) in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top